文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

骨髓增生异常综合征患者异基因造血干细胞移植前评估IPSS-R与WPSS的预后意义

[The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

回顾性分析184例接受allo-HSCT的MDS患者,在初诊及移植前进行IPSS-R与WPSS评分。移植前IPSS-R>3.5分是OS和PFS的独立不良预后因素,移植前IPSS-R较初诊改善组预后更好。

要点

  • 移植前IPSS-R>3.5分是OS(HR=2.510)和PFS(HR=2.457)的独立不良预后因素。
  • 移植前IPSS-R改善组2年OS(83.8±4.6)%优于未改善组(69.3±5.8)%。
  • 初诊时IPSS-R和WPSS评分对移植后OS、PFS无显著预后价值。

核心结论

  • 移植前进行IPSS-R评分对行allo-HSCT的MDS患者预后评估有重要价值。
  • 移植前IPSS-R较初诊时改善的患者有着更好的预后。

研究设计与样本

  • 回顾性分析2016年7月至2019年6月于苏州大学附属第一医院行allo-HSCT的184例MDS患者临床资料。
  • 在初诊及移植前两个时间点进行IPSS-R及WPSS评分,比较两者预后评估价值并分析影响移植预后的危险因素。
  • 移植前除外10例转化为急性髓系白血病(AML)的患者,174例可进行IPSS-R及WPSS评估。

主要发现

  • 中位随访21.9(0.5~47.5)个月,2年OS率为(75.1±3.4)%,2年PFS率为(71.6±3.6)%。
  • 2年复发率为(11.9±0.1)%,2年无复发死亡率为(16.5±0.1)%。
  • 初诊时IPSS-R≤3.5分与>3.5分组OS、PFS差异无统计学意义(P=0.409;P=0.724),WPSS≤2分与>2分组OS、PFS差异无统计学意义(P=0.462;P=0.726)。
  • 移植前IPSS-R≤3.5分组OS、PFS率显著优于>3.5分组[OS:(88.6±4.1)%对(65.8±5.3)%,P=0.003;PFS:(87.6±4.2)%对(60.5±5.8)%,P=0.002]。
  • 移植前IPSS-R改善组OS、PFS率显著优于未改善组[OS:(83.8±4.6)%对(69.3±5.8)%,P=0.027;PFS:(82.8±4.4)%对(64.0±7.2)%,P=0.006]。

关键数值与推荐

  • 多因素分析:移植前IPSS-R>3.5分是OS的独立不良预后因素(P=0.021,HR=2.510,95%CI 1.151~5.476)。
  • 多因素分析:移植前TP53突变是OS的独立不良预后因素(P=0.047,HR=2.460,95%CI 1.014~5.971)。
  • 多因素分析:移植前IPSS-R>3.5分是PFS的独立不良预后因素(P=0.017,HR=2.457,95%CI 1.175~5.141)。
  • 多因素分析:移植前细胞遗传学差及极差是PFS的独立不良预后因素(P=0.008,HR=2.765,95%CI 1.305~5.856)。

临床怎么用

  • 移植前进行IPSS-R评分有助于判断行allo-HSCT的MDS患者预后。
  • 移植前IPSS-R较初诊时改善的患者有着更好的预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to explore the prognostic value of the revised international prognostic scoring system (IPSS-R) and the WHO prognostic scoring system (WPSS) in patients with myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: The clinical data of 184 patients with MDS who received allo-HSCT from July 2016 to June 2019 were retrospectively analyzed. IPSS-R and WPSS were performed at diagnosis and before transplantation. The prognostic values of IPSS-R and WPSS and potential risk factors were explored. Results: With a median follow-up of 21.9 (0.5-47.5) months, the two-year overall survival (OS) and progression-free survival (PFS) rates were (75.1±3.4)% and (71.6±3.6)% , respectively. The two-year cumulative relapse rate and nonrelapse mortality rate were (11.9±0.1)% and (16.5±0.1)% , respectively. There were no significant differences in OS and PFS between the IPSS-R ≤3.5 and >3.5 groups at diagnosis (P=0.409; P=0.724). No significant differences in OS and PFS between the WPSS ≤2 and >2 groups (P=0.426; P=0.726) were observed as well. When the patients were reevaluated before transplantation, the OS and PFS of the IPSS-R ≤3.5 group were significantly better than >3.5 group [OS: (88.6±4.1)% vs (65.8±5.3)% , P=0.003; PFS: (87.6±4.2)% vs (60.5±5.8)% , P=0.002]. However, there were no significant differences in OS and PFS among the WPSS ≤2 and >2 groups (P=0.584; P=0.565). In addition, the OS and PFS of the improved group based on IPSS-R were significantly better than those of the unimproved group before transplantation [OS: (83.8±4.6)% vs (69.3±5.8)% , P=0.027; PFS: (82.8±4.4)% vs. (64.0±7.2)% , P=0.006]. Multivariate analysis indicated that a pretransplant IPSS-R of >3.5 (P=0.021, HR=2.510, 95% CI 1.151-5.476) and TP53 mutation (P=0.047, HR=2.460, 95% CI 1.014-5.971) were independent risk factors for OS, whereas a pretransplant IPSS-R of >3.5 (P=0.017, HR=2.457, 95% CI 1.175-5.141) and pretransplant cytogenetic poor and very poor (P=0.008, HR=2.765, 95% CI 1.305-5.856) were independent risk factors for PFS. Conclusion: A pretransplantation evaluation of IPSS-R could help determine the prognosis of patients with MDS undergoing allo-HSCT. In addition, patients with improved IPSS-R scores before undergoing allo-HSCT had a better prognosis. 目的: 探究不同时间进行修订版国际预后积分系统(IPSS-R)及WHO预后积分系统(WPSS)评分对异基因造血干细胞移植(allo-HSCT)治疗骨髓增生异常综合征(MDS)患者的预后评估价值。 方法: 回顾性分析2016年7月至2019年6月于苏州大学附属第一医院行allo-HSCT的184例MDS患者临床资料,在初诊及移植前两个时间点进行IPSS-R及WPSS评分,比较两者预后评估价值,分析影响移植预后的危险因素。 结果: 中位随访21.9(0.5~47.5)个月,移植后2年总体生存(OS)、无进展生存(PFS)率分别为(75.1±3.4)%、(71.6±3.6)%,2年复发(RR)率和无复发死亡率(NRM)分别为(11.9±0.1)%、(16.5±0.1)%。初诊时IPSS-R≤3.5分与>3.5分组OS、PFS差异无统计学意义(P=0.409;P=0.724),WPSS≤2分与>2分组OS、PFS差异无统计学意义(P=0.462;P=0.726)。移植前除外10例患者转化为急性髓系白血病(AML),174例患者可进行IPSS-R及WPSS评估,其中IPSS-R≤3.5分组OS、PFS率显著优于>3.5分组[OS:(88.6±4.1)%对(65.8±5.3)%,P=0.003;PFS:(87.6±4.2)%对(60.5±5.8)%,P=0.002],WPSS≤2分与>2分组间OS、PFS差异无统计学意义(P=0.584;P=0.565)。此外,移植前IPSS-R较初诊时相比改善组OS、PFS率显著优于未改善组[OS:(83.8±4.6)%对(69.3±5.8)%,P=0.027;PFS:(82.8±4.4)%对(64.0±7.2)%,P=0.006],多因素分析发现移植前TP53突变(P=0.047,HR=2.460,95% CI 1.014~5.971)和移植前IPSS-R>3.5分(P=0.021,HR=2.510,95% CI 1.151~5.476)是影响OS的独立不良预后因素,移植前细胞遗传学差及极差(P=0.008,HR=2.765,95% CI 1.305~5.856)和移植前IPSS-R>3.5分(P=0.017,HR=2.457,95% CI 1.175~5.141)是影响PFS的独立不良预后因素。 结论: 移植前进行IPSS-R评分对行allo-HSCT的MDS患者的预后评估有重要价值,移植前IPSS-R较初诊时改善的患者有着更好的预后。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lu CQ, Hou C, Wang P, et al. [The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35405784. doi:10.3760/cma.j.issn.0253-2727.2022.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。